pocketful logo
Genpharmasec Ltd logo

Genpharmasec Ltd

NSE: BSE: 531592

1.18

(-9.23%)

Wed, 11 Mar 2026, 11:08 am

Genpharmasec Analysis

dividend

thumbs up icon

Pros

    thumbs up icon

    Cons

    • Unable to evaluate Generic Pharmasec's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
    • Unable to evaluate Generic Pharmasec's dividend against the top 25% market benchmark as the company has not reported any payouts.

    health

    thumbs up icon

    Pros

    • Generic Pharmasec is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
    • Generic Pharmasec is profitable, therefore cash runway is not a concern.
    • Generic Pharmasec is profitable, therefore cash runway is not a concern.
    • Generic Pharmasec has no debt, it does not need to be covered by operating cash flow.
    • Generic Pharmasec has no debt, it does not need to be covered by short term assets.
    • Generic Pharmasec's cash and other short term assets cover its long term commitments.
    • Generic Pharmasec currently has no debt however we can't compare to 5 years ago as we have no data for that period.
    • Generic Pharmasec has no debt, therefore coverage of interest payments is not a concern.
    • Generic Pharmasec has no debt.
    • Low level of unsold assets.
    thumbs up icon

    Cons

      management

      thumbs up icon

      Pros

        thumbs up icon

        Cons

        • The average tenure for the Generic Pharmasec board of directors is less than 3 years, this suggests a new board.

        misc

        thumbs up icon

        Pros

          thumbs up icon

          Cons

          • Generic Pharmasec is not covered by any analysts.
          • Generic Pharmasec has significant price volatility in the past 3 months.

          past

          thumbs up icon

          Pros

          • Generic Pharmasec's 1-year earnings growth exceeds its 5-year average (248.2% vs 59.6%)
          • Generic Pharmasec has delivered over 20% year on year earnings growth in the past 5 years.
          • Generic Pharmasec's earnings growth has exceeded the IN Trade Distributors industry average in the past year (248.2% vs 30.2%).
          thumbs up icon

          Cons

          • Generic Pharmasec used its assets less efficiently than the IN Trade Distributors industry average last year based on Return on Assets.
          • It is difficult to establish if Generic Pharmasec improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
          • Generic Pharmasec has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).

          value

          thumbs up icon

          Pros

          • 531592 outperformed the Trade Distributors industry which returned -5.6% over the past year.
          • 531592 outperformed the Market in India which returned -14.5% over the past year.
          thumbs up icon

          Cons

          • Generic Pharmasec is overvalued based on assets compared to the IN Trade Distributors industry average.
          • Generic Pharmasec is overvalued based on earnings compared to the IN Trade Distributors industry average.
          • Generic Pharmasec is overvalued based on earnings compared to the India market.
          • BSE:531592 is down -21.7% underperforming the Trade Distributors industry which returned 6.8% over the past month.
          • BSE:531592 is down -21.7% underperforming the market in India which returned 8% over the past month.

          Open Your Free Demat Account Now!

          Step into a world of zero fees and limitless opportunities!

          pocketful logo

          2022-25 Pocketful. All rights reserved, Built with in India

          Version -5.76

          app image 1app image 2

          Explore

          Calculatorsfooter arrow down icon
          Popular Calculatorsfooter arrow down icon
          Group Stocksfooter arrow down icon

          Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800